Prostate cancer drug combo trial halted early – no benefit seen

NCT ID NCT04934722

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early because the combination did not show enough benefit. Participants stopped the study drug and were offered standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

Contacts and locations

Locations

2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0808)

Hangzhou, Zhejiang, 310009, China
Beijing Cancer Hospital ( Site 0802)

Beijing, Beijing Municipality, 100142, China
Chongqing Cancer Hospital ( Site 0815)

Chongqing, Chongqing Municipality, 400030, China
Harbin Medical University Cancer Hospital ( Site 0822)

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital ( Site 0818)

Zhengzhou, Henan, 450008, China
Hubei Cancer Hospital ( Site 0833)

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital ( Site 0817)

Changsha, Hunan, 410013, China
Nanjing Drum Tower Hospital ( Site 0811)

Nanjing, Jiangsu, 210008, China
Ningbo First Hospital-Urology (0835)

Ningbo, Zhejiang, 315010, China
Peking University First Hospital ( Site 0800)

Beijing, Beijing Municipality, 100034, China
Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0807 )

Shanghai, Shanghai Municipality, 200127, China
Southern Medical University Nanfang Hospital ( Site 0838)

Guangzhou, Guangdong, 510515, China
Sun Yat Sen Memorial Hospital (Site # 0819)

Guangzhou, Guangdong, 510220, China
Sun Yat-Sen University Cancer Center ( Site 0825)

Guangzhou, Guangdong, 510060, China
The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 0830)

Hangzhou, Zhejiang, 310009, China
The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 0638)

Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital of Nanchang University ( Site 0821)

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 0834)

Wenzhou, Zhejiang, 325000, China
The First Affiliated Hospital of Xiamen University (Site 0816)

Xiamen, Fujian, 361000, China
The Second Affiliated Hosp of Xi'an Jiaotong Univ College of Medicine ( Site 0831)

Xi'an, Shaanxi, 710004, China
The first affiliated Hospital of Xi an Jiaotong University ( Site # 0812)

Xi’an, Shanxi, 710061, China
Tianjin Medical University Cancer Institute & Hospital ( Site 0804 )

Tianjin, Tianjin Municipality, 300000, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0829)

Wuhan, Hubei, 430000, China
Zhejiang Provincial People's Hospital ( Site 0809)

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.